Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Harpoon Therapeutics, Inc. (HARP)
Last harpoon therapeutics, inc. earnings: 3/12 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023 Completion of $25 million preferred equity financing provides sufficient cash to fund operations into the second half of 2024, beyond key data milestones Five posters on multiple programs to be presented at AACR 2023 in April SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. “Harpoon is well positioned to reach 2023 key milestones on our HPN217 and HPN328 clinical studies with a solid balance sheet extending the cash runway into the second half of 2024,” said Julie Eastland, President and Chief Executive Officer of Harpoon Therapeutics. “Ou
Show less
Read more
Impact Snapshot
Event Time:
HARP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HARP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HARP alerts
High impacting Harpoon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HARP
News
- Merck: A High-Conviction Investment For Long-Term Growth [Seeking Alpha]Seeking Alpha
- Harpoon Therapeutics, Inc. (NASDAQ: HARP) had its "neutral" rating re-affirmed by analysts at Citigroup Inc.. They now have a $23.00 price target on the stock, up previously from $13.00.MarketBeat
- INVESTIGATION ALERT: Halper Sadeh LLC Investigates HARP, TARO, FFNWGlobeNewswire
- STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – HARP, FGH, BBAIAccesswire
- INVESTIGATION ALERT: Halper Sadeh LLC Investigates HARP, JNPR, TGAN, TASTPR Newswire
HARP
Sec Filings
- 3/12/24 - Form EFFECT
- 3/12/24 - Form EFFECT
- 3/12/24 - Form EFFECT
- HARP's page on the SEC website